Evidence map›Paper›PMID 40354485›Full record

ArticlePloS one2025

MALDI imaging mass spectrometry differentiates basal cell carcinoma from trichoblastoma and trichoepithelioma: A proof of principle study.

Jennifer M C Ranes, Jessica L Moore, Nathan H Patterson, Sarah P Nicholson, Sara Kantrow, Jason Robbins, Richard M Caprioloi, Jeremy L Norris, Rami N Al-Rohil

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Jennifer M C RanesSt. George's University School of Medicine, True Blue, Grenada.
Jessica L MooreFrontier Diagnostics, LLC, Nashville, Tennessee, United States of America.
Nathan H PattersonFrontier Diagnostics, LLC, Nashville, Tennessee, United States of America.
Sarah P NicholsonFrontier Diagnostics, LLC, Nashville, Tennessee, United States of America.
Sara KantrowPathology Associates of Saint Thomas, Nashville, Tennessee, United States of America.
Jason RobbinsPathology Associates of Saint Thomas, Nashville, Tennessee, United States of America.
Richard M CaprioloiFrontier Diagnostics, LLC, Nashville, Tennessee, United States of America.
Jeremy L NorrisFrontier Diagnostics, LLC, Nashville, Tennessee, United States of America.
Rami N Al-RohilDuke University Department of Pathology and Dermatology, Durham, North Carolina, United States of America.ORCID https://orcid.org/0000-0002-9431-0530

Funding

A Molecular Diagnostic Assay for Accurately Differentiating Melanoma from Benign LesionsR44CA228897 · NCI · FRONTIER DIAGNOSTICS, LLC · PI HACHEY, DAVID L · 2018 to 2020
$2.2M
NCI NIH HHS R44 CA228897
6 · The paper itself

Abstract

backgroundBasal cell carcinoma (BCC) comprises a large portion of dermatopathology specimens; however, benign mimics such as trichoblastoma/trichoepithelioma (TB/TE) place accurate diagnosis at risk and consequently lead to inappropriate clinical management and overuse of healthcare resources. This study aims to address the challenges of traditional histopathological evaluation by utilizing matrix-assisted laser desorption ionization imaging mass spectrometry (MALDI IMS). METHODS AND

findingsFormalin-fixed paraffin-embedded BCC and TB/TE tissue blocks were taken from archival tissue. A cohort of 69 BCC and TB/TE specimens were identified, each having three concordant diagnoses given by Dermatopathologists after a blinded analysis. H&E stained sections of each specimen were imaged for pathological analysis and uploaded to a digital annotation software with the following classifications: BCC, TB, TE, BCC stroma, TB stroma, and TE stroma. Mass spectra were collected from unstained serial sections guided by the areas annotated by the Dermatopathologists on the H&E stained serial sections. Before informatics, the data from the cohort were divided randomly into a training set (n = 55) and a validation set (n = 14). Prediction models were developed using a support vector machine (SVM) classification model from the training set data. The platform predicted BCC and TB/TE in model 2 (tumor nests alone) with a sensitivity of 98.9% (95% CI 98.3-99.4%) and specificity of 88.4% (95% CI 78.4-94.5%) at the spectral level in the validation set. Model 1 (stroma alone) had a sensitivity of 46.1% (95% CI 43.0-49.1%) and specificity of 99.2% (95% CI 97.1-99.9%). A combined model 3 (tumor nests and stroma) had a sensitivity of 90.26% (95% CI 89.1%-91.3%) and a specificity of 97.1% (95% CI 94.6% to 98.7%). The limitations of this study included a small sample set, which included easily identifiable cases obtained from a single tissue source.

conclusionsOur study proves that BCC and TB/TE exhibit different proteomic profiles that one can use to enable accurate differential diagnosis. While our findings are not yet validated for clinical use, this merits further research to support IMS as an ancillary diagnostic tool for adequately and efficiently identifying the most common cutaneous malignancy in the United States. We recommend that future studies obtain a more extensive set of histologically challenging cases from multiple institutions and adequate clinical follow-up to confirm diagnostic accuracy.

Indexed as

Basal Cell CarcinomaSkin NeoplasmsSpectrometry, Mass, Matrix-Assisted Laser Desorption-IonizationAdultAgedAged, 80 and overDiagnosis, DifferentialFemaleHumansMaleMiddle Aged

Identifiers

PMID40354485
PMCPMC12068704

What OpenQuestion holds

Textmetadata
LicenceCC0
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.